Compare WVE & FA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WVE | FA |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.5B |
| IPO Year | 2015 | 2021 |
| Metric | WVE | FA |
|---|---|---|
| Price | $12.65 | $9.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 4 |
| Target Price | ★ $30.44 | $19.00 |
| AVG Volume (30 Days) | ★ 3.2M | 988.7K |
| Earning Date | 03-03-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $109,230,000.00 | ★ $1,461,496,000.00 |
| Revenue This Year | N/A | $85.19 |
| Revenue Next Year | $16.10 | $4.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 103.75 | 93.41 |
| 52 Week Low | $5.28 | $9.42 |
| 52 Week High | $21.73 | $20.28 |
| Indicator | WVE | FA |
|---|---|---|
| Relative Strength Index (RSI) | 41.05 | 22.13 |
| Support Level | $12.51 | $12.65 |
| Resistance Level | $14.15 | $13.66 |
| Average True Range (ATR) | 0.76 | 0.96 |
| MACD | -0.04 | -0.34 |
| Stochastic Oscillator | 8.29 | 1.46 |
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
First Advantage Corp is a provider of global software and data in the Human Resources technology industry. The company leverages proprietary technology and AI across its platforms, data, and APIs to deliver comprehensive background screening, digital identity, and verification solutions driven by innovation, automation, and customer success. Its reportable segments are First Advantage Americas, First Advantage International, and Sterling. Maximum revenue is generated from the First Advantage Americas segment. The group serves customers in over 200 countries and territories, modernising hiring and onboarding on a global scale.